Skip to main content

Table 1 Patient, tumor, treatment characteristics before and after propensity score matching

From: Role of a multidisciplinary team in administering radiotherapy for esophageal cancer

Variables Before matching After matching
All n = 212 MDT n = 157 Non-MDT n = 55 P All n = 106 MDT n = 53 Non-MDT n = 53 P
Age(y) 64 (44–89) 64 (44–89) 64 (46–88) 0.52 64 (44–89) 63 (44–89) 65 (46–88) 0.56
  < 60 66 (31.1%) 44 (28%) 22 (40%) 0.26 38 (35.8%) 18 (34%) 20 (37.7%) 0.33
60–75 115 (54.2%) 89 (56.7%) 26 (47.3%)   43 (40.6%) 25 (47.2%) 18 (34%)  
  ≥ 75 31 (14.6%) 24 (15.3%) 7 (12.7%)   25 (23.6%) 10 (18.9%) 15 (28.3%)  
Sex
Male 182 (85.8%) 137 (87.3%) 45 (81.8%) 0.32 89 (84%) 45 (84.9%) 44 (83%) 0.79
Female 30 (14.2%) 20 (12.7%) 10 (18.2%)   17 (16%) 8 (15.1%) 9 (17%)  
PS
0–1 197 (92.9%) 146 (93%) 51 (92.7%) 0.37 98 (92.5%) 49 (92.5%) 49 (92.5%) 1
2–3 15 (7.1%) 11 (7%) 4 (7.3%)   8 (7.5%) 4 (7.5%) 4 (7.5%)  
Location
Neck-Upper 42 (19.8%) 30 (19.1%) 12 (21.8%) 0.33 21 (19.8%) 10 (18.9%) 11 (20.8%) 0.81
Middle-Lower 170 (80.2%) 127 (80.9%) 43 (78.2%)   85 (80.2%) 43 (81.1%) 42 (79.2%)  
Histologic type
SCC 196 (92.5%) 145 (92.4%) 51 (92.7%) 0.93 97 (91.5%) 48 (90.6%) 49 (92.5%) 1
Adeno or others 16 (7.6%) 12 (7.6%) 4 (7.3%)   9 (8.5%) 5 (9.4%) 4 (7.5%)  
Stage
I-II 50 (23.6%) 33 (21.6%) 16 (29.1%) 0.52 30 (28.3%) 14 (26.4%) 16 (30.2%) 0.77
III 147 (69.3%) 112 (71.3%) 35 (6360%)   66 (62.3%) 33 (62.3%) 33 (62.3%)  
IV 15 (7.1%) 11 (7%) 4 (7.3%)   10 (9.4%) 6 (11.3%) 4 (7.5%)  
Differentiation
I-II 67 (31.6%) 54 (34.4%) 13 (23.6%) 0.33 27 (25.5%) 14 (26.4%) 13 (24.5%) 0.91
III-IV 57 (26.9%) 41 (26.1%) 16 (29.1%)   28 (26.4%) 13 (24.5%) 15 (28.3%)  
unknown 88 (41.5%) 62 (39.5%) 26 (47.3%)   51 (48.1%) 26 (49.1%) 25 (47.2%)  
Treatment modality
With operation 104 (49.1%) 77 (49%) 27 (49.1%) 1 50 (47.2%) 24 (45.3%) 26 (49.1%) 0.7
non-operation 108 (50.9%) 80 (51%) 28 (50.9%)   56 (52.8%) 29 (54.7%) 27 (50.9%)  
With chemotherapy 171 (80.7%) 133 (84.7%) 38 (69.1%) 0.01 78 (73.6%) 40 (75.5%) 38 (71.7%) 0.66
non-chemotherapy 41 (19.3%) 24 (15.3%) 17 (30.9%)   28 (26.4%) 13 (24.5%) 15 (28.3%)  
  1. SCC squamous cell carcinoma, MDT multidisciplinary team